Abstract:BACKGROUND: Epidermal growth factor receptor (EGFR) exon 20 insertion (EGFR ex20ins) is a common mutation in non-small cell lung cancer (NSCLC). Patients with EGFR ex20ins generally respond poor to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). EGFR ex20ins are often co-occurring with EGFR amplification. However, the impact of EGFR amplification on the survival of patients with EGFR ex20ins mutations has not been determined.METHODS: This is an observational longitudinal cohort study. A prospectively managed database included consecutive treatment-naïve adult patients with advanced NSCLC and EGFR ex20ins confirmed by next-generation sequencing (NGS) at Guangdong Provincial People's Hospital between November 2017 and February 2019. The participants were enrolled from the database and extracted their clinical characteristics, treatment and clinical outcomes. NGS was used to establish whether EGFR amplification was present in tumor tissue. Overall survival (OS) and progression-free survival (PFS) were compared between EGFR amplification and non-EGFR amplification groups using the Kaplan-Meier method and log-rank test. Subgroup analyses were performed based on the treatment used (EGFR-TKI or chemotherapy).RESULTS: Fifteen different EGFR ex20ins mutation subtypes were identified in the 39 patients included in the analysis, and the most common subtypes were p.A767_D770dup (25.6%), p.S768_D770dup (23.1%) and p.N771_H773dup (10.3%). Among 31 patients with EGFR ex20ins mutations and NGS data for tumor tissue, EGFR amplification was identified in 12 patients (38.7%) and there were no significant differences in clinical characteristics. Among 26 patients, there were no significant differences between the EGFR amplification (n=11) and non-EGFR amplification (n=15) groups in median OS (715 vs. 452 days, P=0.912). Among 20 patients administered chemotherapy, there were no significant differences between the EGFR amplification and non-EGFR amplification groups in median PFS (206 vs. 112 days, P=0.425). Among 24 patients administered an EGFR-TKI, median PFS was longer in the non-EGFR amplification group than in the EGFR amplification group (110 vs. 31 days, P=0.030).CONCLUSIONS: There is a tendency that EGFR amplification might be a poor predictor in EGFR ex20ins-positive NSCLC patients treated with EGFR-TKIs.

Amplification of Epidermal Growth Factor Receptor (EGFR) Gene in Chinese Gliomas and Its Influence to Prognosis

Pathological Significance of Epidermal Growth Factor Receptor Expression and Amplification in Human Gliomas

Expression of Dedifferentiation Markers and Multilineage Markers in U251 Glioblastoma Cells with Silenced EGFR and FGFR Genes.

[The Association Between EGFR Gene Amplification and the Prognosis in Non-small Cell Lung Cancer: A Meta-Analysis.].

Prognostic Implications of Epidermal Growth Factor Receptor Variant III Expression and Nuclear Translocation in Chinese Human Gliomas

The analysis of EGFR variants in Chinese adult glioblastoma patients.

Evaluation Of Epidermal Growth Factor Receptor (Egfr) By Chromogenic In Situ Hybridization (Cish (Tm)) And Immunohistochemistry (Ihc) In Archival Gliomas Using Bright-Field Microscopy

EGFR mutation: a prognostic factor associated with immune infiltration in lower-grade glioma.

Predicting Epidermal Growth Factor Receptor Gene Amplification Status in Glioblastoma Multiforme by Quantitative Enhancement and Necrosis Features Deriving from Conventional Magnetic Resonance Imaging

EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study

Effect of EGFR amplification on survival of patients with EGFR mutation-positive non-small cell lung cancer.

FGFR1 Amplification and EGFR Mutation in Chinese Squamous Cell Lung Cancer.

The Crosstalk between the EGFR and IFN-γ Pathways and Synergistic Roles in Survival Prediction and Immune Escape in Gliomas

The Prognostic Value of EGFR Overexpression and Amplification in Esophageal Squamous Cell Carcinoma

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Prognostic Value of Fgfr1 Overexpression and Amplification in Esophageal Squamous Cell Carcinoma Patients: A Combined Analysis from Tcga Database

High Amplification of FGFR1 Gene is a Delayed Poor Prognostic Factor in Early Stage ESCC Patients

Epidermal Growth Factor Receptor Protein Overexpression and Gene Amplification Are Associated with Aggressive Biological Behaviors of Esophageal Squamous Cell Carcinoma.

Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.

Clinical roles of EGFR amplification in diffuse gliomas: A real-world study using the 2021 WHO classification of CNS tumors

Comprehensive Analysis Reveals Epithelial Growth Factor Receptor as a Potential Diagnostic Biomarker in Glioblastoma Multiforme